CYP2D6 inhibitors

Choice of Antidepressant May Affect Survival in Women on Tamoxifen for Breast Cancer

Tamoxifen is a SERM (selective estrogen receptor modulator) used in women with breast cancer; it reduces the risk of relapse and improves overall survival.  Tamoxifen may also be used to reduce the risk of breast cancer in women at high risk for the disease. In order to be fully effective, tamoxifen must be metabolized to an active metabolite, endoxifen, by the liver enzyme CYP2D6. Consequently, any co-administered agent that inhibits this enzyme will reduce the conversion of tamoxifen to endoxifen, thereby potentially reducing the efficacy of tamoxifen as a breast cancer therapy.

By |2019-11-03T22:28:44-04:00May 2nd, 2011|Antidepressants, Breast Cancer|Comments Off on Choice of Antidepressant May Affect Survival in Women on Tamoxifen for Breast Cancer
Go to Top